Skip to main content

Advertisement

SpringerLink
Log in

Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

APP23 mice are a promising model of Alzheimer’s disease, expressing several histopathological, cognitive and behavioural hallmarks of the human condition. A valid animal model should respond to therapeutic interventions in an equivalent manner as human patients.

Objectives

To further validate the APP23 model, we examined whether cognitive deficits could be antagonised by donepezil, rivastigmine, galantamine or memantine, which are approved drugs for symptomatic treatment of dementia.

Methods

Animals were tested at an age at which untreated APP23 mice display severe deficits in visual–spatial learning. Four-month-old APP23 mice and control littermates were administered donepezil (0.3 or 0.6 mg kg−1), rivastigmine (0.5 or 1.0 mg kg−1), galantamine (1.25 or 2.5 mg kg−1), memantine (2 or 10 mg kg−1) or saline through daily i.p. injections. After 1 week of treatment, acquisition phase commenced, with daily treatment continuing during cognitive testing.

Results

All cholinesterase inhibitors reduced cognitive deficits with the following optimal daily doses: galantamine 1.25 mg kg−1, rivastigmine 0.5 mg kg−1 and donepezil 0.3 mg kg−1. Higher dosages often did not exert beneficial effects in accordance with inverted U-shaped dose–response curves described for cholinomimetics. Symptomatic efficacy of memantine on cognition was mild, with significant amelioration manifesting during probe trial.

Conclusions

This is the first study to simultaneously evaluate the efficacy of therapeutically relevant doses of these four compounds in one particular learning and memory paradigm, being the Morris water maze. The fact that symptomatic intervention was able to diminish cognitive impairment, substantially adds to the validity of the APP23 model as a valuable tool to evaluate future therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A (1997) Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 280:1117–1136

    CAS  PubMed  Google Scholar 

  • Anand R, Gharabawi G, Enz A (1996) Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer’s disease: an overview. J Drug Dev Clin Pract 8:109–116

    Google Scholar 

  • Baldi E, Lorenzini CA, Corrado B (2003) Task solving by procedural strategies in the Morris water maze. Physiol Behav 78:785–793

    Article  Google Scholar 

  • Ballard TM, McAllister KH (1999) The acetylChE inhibitor, ENA 713 (Exelon), attenuates the working memory impairment induced by scopolamine in an operant DNMTP task in rats. Psychopharmacology 146:10–18

    Article  Google Scholar 

  • Barnes CA, Danysz W, Parsons CG (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8:565–571

    Google Scholar 

  • Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495–529

    Article  Google Scholar 

  • Bejar C, Wang RH, Weinstock M (1999) Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol 383:231–240

    Article  CAS  PubMed  Google Scholar 

  • Boncristiano S, Calhoun ME, Kelly PH, Pfeifer M, Bondolfi L, Stalder M, Phinney AL, Abramowski D, Sturchler-Pierrat C, Enz A, Sommer B, Staufenbiel M, Jucker M (2002) Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci 22:3234–3243

    Google Scholar 

  • Braida D, Sala M (2001) Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev 7:369–386

    Google Scholar 

  • Braida D, Paladini E, Griffini P, Lamperti M, Maggi A, Sala M (1996) An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur J Pharmacol 302:13–20

    Article  Google Scholar 

  • Cain DP, Saucier D, Hall J, Hargreaves EL, Boon F (1996) Detailed behavioral analysis of water maze acquisition under APV or CNQX: contribution of sensorimotor disturbances to drug-induced acquisition deficits. Behav Neurosci 110:86–102

    Article  Google Scholar 

  • Cain DP, Saucier D, Boon F (1997) Testing hypotheses of spatial learning: the role of NMDA receptors and NMDA-mediated long-term potentiation. Behav Brain Res 84:179–193

    Article  Google Scholar 

  • Camacho F, Smith CP, Vargas HM, Winslow JT (1996) Alpha 2-adrenoceptor antagonists potentiate acetylChE inhibitor effects on passive avoidance learning in the rat. Psychopharmacology (Berl) 124:347–354

    Google Scholar 

  • Chen SY, Wright JW, Barnes CD (1996) The neurochemical and behavioral effects of beta-amyloid peptide(25–35). Brain Res 720:54–60

    Article  Google Scholar 

  • Chen Z, Xu AJ, Li R, Wei EQ (2002) Reversal of scopolamine-induced spatial memory deficits in rats by TAK-147. Acta Pharmacol Sin 23:355–360

    CAS  PubMed  Google Scholar 

  • Corey-Bloom J, Anand R, Veach J (1998) A randomised trial evaluating the efficacy and safety of Ena 713 (rivastigmine tartrate), a new acetylChE inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1:55–65

    Google Scholar 

  • Coyle JT, Price DL, DeLong MR (1983) Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219:1184–1190

    Google Scholar 

  • Dajas-Bailador FA, Heimala K, Wonnacott S (2003) The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. Mol Pharmacol 64:1217–1226

    Article  Google Scholar 

  • Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2:1403

    Article  Google Scholar 

  • Davies P, Wolozin BL (1987) Recent advances in the neurochemistry of Alzheimer’s disease. J Clin Psychiatry 48:23–30

    Google Scholar 

  • Dawson GR, Iversen SD (1993) The effects of novel ChE inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res 57:143–153

    Article  Google Scholar 

  • De Deyn PP, D’Hooge R, van Zutphen LFM (2000) Animal models of human disorders—general aspects. Neurosci Res Commun 26:141–148

    Google Scholar 

  • D’Hooge R, De Deyn PP (2001) Applications of the Morris water maze in the study of learning and memory. Brain Res Rev 36:60–90

    Article  Google Scholar 

  • D’Hooge R, Nagels G, Westland CE, Mucke L, De Deyn PP (1996) Spatial learning deficit in mice expressing human 751-amino acid beta-amyloid precursor protein. NeuroReport 7:2807–2811

    Google Scholar 

  • D’Hooge R, Franck F, Mucke L, De Deyn PP (1999) Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. Eur J Neurosci 11:4398–4402

    Article  Google Scholar 

  • Ditzler K (1991) Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 41:773–780

    Google Scholar 

  • Doble A (1999) The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81:163–221

    Article  Google Scholar 

  • Enz A, Amstutz R, Hofmann A, Gmelin G, Kelly PH (1989) Pharmacological properties of the preferentially centrally acting acetylcholinesterase inhibitor SDZ ENA 713. In: Kewitz, Thomson, Bickel (eds) Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer’s disease). Zuckswerdt Verlag, München, pp 271–277

    Google Scholar 

  • Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J (1993) Brain selective inhibition of acetylChE: a novel approach to therapy for Alzheimer’s disease. Prog Brain Res 98:431–438

    Google Scholar 

  • Fishkin RJ, Ince ES, Carlezon WA Jr, Dunn RW (1993) d-Cycloserine attenuates scopolamine-induced learning and memory deficits in rats. Behav Neural Biol 59:150–157

    Article  Google Scholar 

  • Flood JF, Landry DW, Jarvik ME (1981) Cholinergic receptor interactions and their effects on long-term memory processing. Brain Res 215:177–185

    Article  Google Scholar 

  • Görtelmeyer R, Erbler H (1992) Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung 42:904–913

    Google Scholar 

  • Hodges H (1996) Maze procedures: the radial-arm and water maze compared. Brain Res Cogn Brain Res 3:167–181

    Article  Google Scholar 

  • Hoh TE, Cain DP (1997) Fractionating the nonspatial pretraining effect in the water maze task. Behav Neurosci 111:1285–1291

    Article  Google Scholar 

  • Kelly PH, Hunziker D, Schlecht HP, Carver K, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Sommer B (1999) Progressive behavioural impairment in amyloid precursor protein transgenic mouse line APP23. Soc Neurosci Abstr 25:1291

    Google Scholar 

  • Kelly PH, Bondolfi L, Hunziker D, Schlecht HP, Carver K, Maguire E, Abramowski D, Wiederhold KH, Sturchler-Pierrat C, Jucker M, Bergmann R, Staufenbiel M, Sommer B (2003) Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging 24:365–378

    Article  Google Scholar 

  • Koob GF (2000) Neurobiology of addiction. Toward the development of new therapies Ann NY Acad Sci 909:170–185

    CAS  PubMed  Google Scholar 

  • Lalonde R, Dumont M, Staufenbiel M, Sturchler-Pierrat C, Strazielle C (2002) Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res. 956:36–44

    Article  Google Scholar 

  • Levi MS, Borne RF (2002) A review of chemical agents in the pharmacotherapy of addiction. Curr Med Chem 9:1807–1818

    Google Scholar 

  • Lilienfeld S (2002) Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev 8:159–176

    Google Scholar 

  • Lindner MD (1997) Reliability, distribution, and validity of age-related cognitive deficits in the Morris water maze. Neurobiol Learn Mem 68:203–220

    Article  Google Scholar 

  • Maelicke A (2000) Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer’s disease. Dement Geriatr Cogn Disord 11:11–18

    Article  Google Scholar 

  • Maldonado C, Cauli O, Rodriguez-Arias M, Aguilar MA, Minarro J (2003) Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal. Behav Brain Res 144:25–35

    Article  Google Scholar 

  • McKeith I, Truyen L, Lilienfeld S, Mahableshwarkar A, Gal-GBR Study Team (2003) Galantamine demonstrates superior efficacy on attention and MMSE compared with donepezil in patients with Alzheimer’s disease actively treated for 52 weeks: an initial analysis. Neurology 60(Suppl 5):A141

    Google Scholar 

  • Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G (2002) Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1–40). Brain Res 958:210–221

    Article  Google Scholar 

  • Misztal M, Frankiewicz T, Parsons CG, Danysz W (1996) Learning deficits induced by chronic intraventricular infusion of quinolinic acid–protection by MK-801 and memantine. Eur J Pharmacol 296:1–8

    Article  Google Scholar 

  • Mohr E, Carter C, Wallin A (1990) Neurochemical substrates of human aging and dementia. Pharmacopsychiatry 23:53–55

    Google Scholar 

  • Moller HJ (1999) Reappraising neurotransmitter-based strategies. Eur Neuropsychopharmacol 9:S53–S59

    Article  Google Scholar 

  • Newhouse PA, Potter A, Levin ED (1997) Nicotinic system involvement in Alzheimer’s and Parkinson’s diseases. Implications for therapeutics. Drugs Aging 11:206–228

    Google Scholar 

  • Niigawa H, Tanimukai S, Takeda M, Hariguchi S, Nishimura T (1995) Effects of SDZ ENA 713, novel acetylChE inhibitor, on learning in rats with basal forebrain lesions. Prog Neuro-Psychopharmacol Biol Psychiatry 19:171–186

    Article  Google Scholar 

  • Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000) Donepezil, a centrally acting acetylChE inhibitor, alleviates learning deficits in hypocholinergic models in rats. Methods Find Exp Clin Pharmacol 22:89–95

    CAS  PubMed  Google Scholar 

  • Ohara T, Fukaya H, Tanaka K, Seno N (1997a) Ameliorating effects of SDZ ENA 713 on age-associated decreases in learning performance and brain choline acetyltransferase activity in rats. Brain Res Bull 43:39–42

    Article  Google Scholar 

  • Ohara T, Takeda M, Fukaya H, Demura N, Iimura A, Seno N (1997b) SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats. Behav Brain Res 83:229–233

    Article  Google Scholar 

  • Parsons CG, Danysz W, Quack G (1999) Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data. Neuropharmacology 38:735–767

    Article  Google Scholar 

  • Piasecki J, Koros E, Dyr W, Kostowski W, Danysz W, Bienkowski P (1998) Ethanol-reinforced behaviour in the rat: effects of uncompetitive NMDA receptor antagonist, memantine. Eur J Pharmacol 354:135–143

    Article  Google Scholar 

  • Popik P, Danysz W (1997) Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-d-aspartate receptor antagonist, memantine. J Pharmacol Exp Ther 280:854–865

    Google Scholar 

  • Rao VL, Dogan A, Todd KG, Bowen KK, Dempsey RJ (2001) Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res 911:96–100

    Article  Google Scholar 

  • Raskind MA, Peskind ER, Wessel T, Yuan W, Galantamine USA-1 Study Group (2000) Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54:2261–2268

    Google Scholar 

  • Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, Memantine Study Group (2003) Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 348:1333–1341

    Article  Google Scholar 

  • Rogers SL, Doody RS, Pratt RD, Ieni JR (2000) Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 10:195–203

    Article  Google Scholar 

  • Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. Br Med J 318:633–638

    Google Scholar 

  • Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lubbert H, Albuquerque EX, Maelicke A (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305:1024–1036

    Article  Google Scholar 

  • Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A (1996) Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49:1–6

    Google Scholar 

  • Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766

    CAS  PubMed  Google Scholar 

  • Strong R (1998) Neurochemical changes in the aging human brain: implications for behavioral impairment and neurodegenerative disease. Geriatrics 53:S9–S12

    Google Scholar 

  • Sturchler-Pierrat C, Staufenbiel M (2000) Pathogenic mechanisms of Alzheimer’s disease analyzed in the APP23 transgenic mouse model. Ann NY Acad Sci 920:134–139

    Google Scholar 

  • Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94:13287–13292

    Article  Google Scholar 

  • Sugimoto H, Ogura H, Arai Y, Limura Y, Yamanishi Y (2002) Research and development of donepezil hydrochloride, a new type of acetylChE inhibitor. Jpn J Pharmacol 89:7–20

    Article  Google Scholar 

  • Sutherland RJ, Hamilton DA (2004) Rodent spatial navigation: at the crossroads of cognition and movement. Neurosci Biobehav Rev 28:687–697

    Article  Google Scholar 

  • Suzuki M, Yamaguchi T, Ozawa Y, Iwai A, Yamamoto M (1995) Effect of YM796, a novel muscarinic agonist, on the impairment of passive avoidance response in senescence-accelerated mice. Pharmacol Biochem Behav 51:623–626

    Article  Google Scholar 

  • Sweeney JE, Bachman ES, Coyle JT (1990) Effects of different doses of galantamine, a long-acting acetylChE inhibitor, on memory in mice. Psychopharmacology 102:191–200

    Google Scholar 

  • Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding CA (2000) 5-Month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54:2269–2276

    CAS  PubMed  Google Scholar 

  • Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317–324

    Article  Google Scholar 

  • Thomsen T, Kewitz H (1990) Selective inhibition of human acetylChE by galantamine in vitro and in vivo. Life Sci 46:1553–1558

    Article  Google Scholar 

  • Tohda C, Tamura T, Komatsu K (2003) Repair of amyloid beta(25–35)-induced memory impairment and synaptic loss by a Kampo formula, Zokumei-to. Brain Res 990:141–147

    Article  Google Scholar 

  • Ueki A, Miyoshi K (1991) Reversal of learning impairment in ventral globus pallidus-lesioned rats by combination of continuous intracerebroventricular choline infusion and oral cholinergic drug administration. Brain Res 547:99–109

    Article  Google Scholar 

  • Van Dam D, D’Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP (2003) Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 17:388–396

    Article  Google Scholar 

  • Van Dam D, Marescau B, Engelborghs S, Cremers T, Mulder J, Staufenbiel M, De Deyn PP. Analysis of cholinergic markers, biogenec amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochem Int (in press a)

  • Van Dam D, Vloeberghs E, Abramowski D, Staufenbiel M, De Deyn PP (accepted) APP23 mice as a model of Alzheimer’s Disease—an example of a transgenic breeding approach to modeling a CNS disorder. CNS Spectr (in press b)

  • Vloeberghs E, Van Dam D, Engelborghs S, Nagels G, Staufenbiel M, De Deyn PP (2004) Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur J Neurosci 20:2757–2766

    Article  Google Scholar 

  • Waite JJ, Thal LJ (1995) The behavioral effects of heptylphysostigmine on rats lesioned in the nucleus basalis. Neurosci Res 21: 251–259

    Article  Google Scholar 

  • Wang T, Tang XC (1998) Reversal of scopolamine-induced deficits in radial maze performance by (−)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol 349:137–142

    Article  Google Scholar 

  • Wanibuchi F, Nishida T, Yamashita H, Hidaka K, Koshiya K, Tsukamoto S, Usuda S (1994) Characterization of a novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in vivo pharmacological studies. Eur J Pharmacol 265:151–158

    Article  Google Scholar 

  • Wehner JM, Balogh SA (2003) Phenotyping mice for learning and memory: traditional tasks, modifications of traditional tasks, and the application of new tasks. In: Crawley J (ed) Mouse behavioral phenotyping. Society for Neuroscience, Washington, DC, pp 13–23

    Google Scholar 

  • Weinstock M, Razin M, Chorev M, Enz A (1994) Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylChE inhibitors. J Neural Transm Suppl 43:219–225

    Google Scholar 

  • Wenk GL, Danysz W, Mobley SL (1995) MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 293:267–270

    Google Scholar 

  • Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer’s disease. J Neurosci 22:1858–1867

    Google Scholar 

  • Wilcock GK, Lilienfeld S, Gaens E (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group Br Med J 321:1445–1449

    Google Scholar 

  • Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, Bullock R, Kershaw P, GAL-GBR-2 Study Group (2003) A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s disease. Drugs Aging 20:777–789

    Google Scholar 

  • Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS (2002) A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s disease. Int J Clin Pract 56:441–446

    Google Scholar 

  • Winblad B, Poritis N (1999) Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14:135–146

    Article  Google Scholar 

  • Wright JW, Alt JA, Turner GD, Krueger JM (2004) Differences in spatial learning comparing transgenic p75 knockout, New Zealand Black, C57BL/6, and Swiss Webster mice. Behav Brain Res 153:453–458

    Article  Google Scholar 

  • Yoshida S, Suzuki N (1993) Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats. Eur J Pharmacol 250:117–124

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Fund for Scientific Research-Flanders (FWO), agreement between Born-Bunge Institute and the University of Antwerp, the Medical Research Foundation Antwerp, and Neurosearch Antwerp. D.V.D. is a research assistant of the FWO.

Author information

Authors and Affiliations

  1. Laboratory of Neurochemistry and Behaviour, Born-Bunge Institute, Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium

    Debby Van Dam & Peter Paul De Deyn

  2. Novartis Institutes of Biomedical Research Basel, 4002, Basel, Switzerland

    Dorothee Abramowski & Matthias Staufenbiel

  3. Department of Neurology/Memory clinic, Middelheim General Hospital, ZINA, Lindendreef 1, 2020, Antwerp, Belgium

    Peter Paul De Deyn

Authors
  1. Debby Van Dam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dorothee Abramowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Staufenbiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Paul De Deyn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Paul De Deyn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Dam, D., Abramowski, D., Staufenbiel, M. et al. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology 180, 177–190 (2005). https://doi.org/10.1007/s00213-004-2132-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-004-2132-z

Keywords

Search

Navigation